The Journal of clinical endocrinology and metabolism
The most recent articles from:
April 2011
-
J. Clin. Endocrinol. Metab. · Apr 2011
Randomized Controlled Trial Multicenter StudyEffects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Denosumab treatment for 24 months increased bone mineral density (BMD) and reduced bone turnover markers (BTM) in postmenopausal women. ⋯ In postmenopausal women with low BMD, the effects of 60 mg denosumab treatment for 24 months on BMD and BTM are reversible upon discontinuation, reflecting its biological mechanism of action. Residual BMD measurements remained above those of the group previously treated with placebo.